InflaRx (IFRX) Net Margin (2018 - 2026)

InflaRx (IFRX) posted Net Margin of 349.45% for Q1 2026, up 371.2% sequentially from 74.16% in Q4 2025, and up 2342025.0% YoY from N/an in Q1 2025.

InflaRx (IFRX) Net Margin (2018 - 2026) Analysis & Trends

InflaRx has reported Net Margin for 9 years, with the latest figure at 349.45% in Q1 2026.

Quarterly Net Margin rose 2342025.0% year-over-year to 349.45% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.11% (up 94.0% YoY) and the FY2025 annual result came in at 95.14%, down 824.0% from the prior year.
Net Margin advanced to 349.45% in Q1 2026 per IFRX's latest filing, from 74.16% in the prior quarter.
Over five years, Net Margin peaked at 6841.98% in Q4 2022 and troughed at 223352.29% in Q1 2023.
A 5-year average of 34265.38% and a median of 0.01% in 2023 frame the typical range for Net Margin.
The sharpest annual moves came in 2022 and 2024: Net Margin sank 60201289 bps in 2022, then jumped 19655418 bps in 2024.
Over 5 years, Net Margin stood at 6841.98% in 2022, then sank by 100 bps to 27.35% in 2023, then soared by 404 bps to 83.02% in 2024, then declined by 11 bps to 74.16% in 2025, then soared by 371 bps to 349.45% in 2026.
According to Business Quant data, Net Margin over the past three periods registered 349.45%, 74.16%, and 51452.32% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	InflaRx	135.25 Mn	-49.00 Mn	2.74 Bn	-15,905.90%

Download Data